Biosense Webster and Medtronic collaborate to advance cardiac arrhythmia
10 May 2007
Diamond Bar, Calif. & Minneapolis, USA. Biosense Webster,
Inc. and Medtronic, Inc. (NYSE:MDT), have announced plans to collaborate on
a clinical trial, educational initiatives and a product development program,
to advance the care of patients with cardiac arrhythmias.
Under the terms
of the agreement, the two companies plan to collaborate in three key areas
of interest: a clinical trial, a technology development initiative and
educational programs. The companies intend to design the clinical trial to
create a new care pathway for identifying candidates most likely to have a
successful ablation treatment outcome and increase the acceptance of
The initiative was announced at Heart Rhythm 2007, the
US Heart Rhythm Society’s 28th Annual Scientific Sessions, taking place in
Denver May 9-12.
“This new strategic alliance will leverage the unique resources and
technologies of the two companies together, and will benefit the millions of
patients who suffer from cardiac arrhythmias around the world,” said Roy
Tanaka, President, Biosense Webster, Inc.
“Medtronic is intently focused on researching and exploring ways to
utilize existing or new technologies for electrophysiologists to better
identify and treat patients with cardiac arrhythmias,” said Steve Mahle,
President of Medtronic’s Cardiac Rhythm Disease Management business. “This
collaboration will begin by bringing the unique competencies of imaging and
navigation together with diagnostics and monitoring in an effort to improve
the electrophysiologist’s capability in identifying and treating patients.
We look forward to collaborating with Biosense Webster to deliver exciting
results for our customers.”
In addition, the two companies will work
together to advance patient care through a joint research and development
program. The companies plan to integrate specific technologies to provide
novel, new solutions for the treatment of complex cardiac arrhythmias.
Lifetime education of physicians is a hallmark of both Biosense Webster and
Medtronic. Through this relationship, the companies will collaborate to
combine resources to extend existing educational opportunities as well as
create new instructional programs for electrophysiologists and allied health
professionals who work in the arrhythmias field.
“With Biosense Webster, we can continue our commitment to education of
physicians at all stages of their career,” said Mahle. “The field of
electrophysiology is always changing and advancing and it is vital that
physicians and other health care professionals who work in this field are
up-to-date on the latest technologies designed to help patients.”